Dual blockade of CTLA-4 and PD-1 is currently being evaluated in numerous clinical trials for advanced solid tumors, such as head and neck squamous cell carcinoma (HNSCC) and glioblastomas (NCT04080804, NCT04606316). Here, PDCD1 is linked to glioblastoma.